Zymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual Meeting

Zymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual Meeting

New clinical data from Phase 1 trial of ZW191 to be presented in an oral presentation on April 21 Preclinical data highlight combination potential for ZW191, a folate receptor alpha (FR⍺)-targeting antibody-drug conjugate (ADC) New ADC candidates, including Z…

Title: Design and evaluation of mRNA translation inhibitors for use as antibody drug conjugate payloadsAbstract: 2062Session: ChemistryDate/Time: Monday, April 20, 2026 at 9:00 am 12:00 pm PST A nov… [+7296 chars]